Literature DB >> 7522877

Evaluation of a novel automated protocol for the collection of peripheral blood stem cells mobilized with chemotherapy or chemotherapy plus G-CSF using the Fresenius AS104 cell separator.

L Pierelli1, G Menichella, A Paoloni, M Vittori, M L Foddai, R Serafini, C Rumi, H Mitschulat, P L Rossi, G Scambia.   

Abstract

Forty-seven peripheral blood stem cell (PBSC) collections were carried out on patients mobilized with chemotherapy and 63 on patients mobilized with chemotherapy plus G-CSF (Filgrastim), using the Fresenius AS104 cell separator and a novel automated PBSC collection protocol. As expected, cell yields were significantly higher in the series mobilized using chemotherapy plus G-CSF. The low platelet and red blood cell contamination permitted freezing of the apheresis product without further manipulation, other than plasma removal in both series. In patients mobilized with chemotherapy we obtained a MNC and a hemopoietic progenitor (CFU-GM, BFU-e, and CD34+ cells) collection efficiency comparable or superior to those reported by Bender (1992) with the Baxter CS3000 Plus after mobilization with cyclophosphamide. A significant decrease in MNC, BFU-e, and CD34+ cell collection efficiency was found in patients mobilized with chemotherapy plus G-CSF compared to those obtained in patients mobilized with chemotherapy alone. Ten patients achieved a prompt and stable engraftment after high dose chemotherapy and the infusion of cryopreserved PBSC collected using this protocol. Studies are in progress in order to improve MNC and hemopoietic progenitor collection efficiency in patients mobilized with G-CSF to obtain a graft in no more than one or two procedures.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7522877     DOI: 10.1089/scd.1.1993.2.145

Source DB:  PubMed          Journal:  J Hematother        ISSN: 1061-6128


  2 in total

1.  High-dose carboplatin, etoposide and melphalan (CEM) with peripheral blood progenitor cell support as late intensification for high-risk cancer: non-haematological, haematological toxicities and role of growth factor administration.

Authors:  P Benedetti Panici; L Pierelli; G Scambia; M L Foddai; M G Salerno; G Menichella; M Vittori; F Maneschi; U Caracussi; R Serafini; G Leone; S Mancuso
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

2.  In vitro effect of amifostine on haematopoietic progenitors exposed to carboplatin and non-alkylating antineoplastic drugs: haematoprotection acts as a drug-specific progenitor rescue.

Authors:  L Pierelli; G Scambia; A Fattorossi; G Bonanno; A Battaglia; A Perillo; G Menichella; P B Panici; G Leone; S Mancuso
Journal:  Br J Cancer       Date:  1998-10       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.